DR. STEVEN KENNETH LIBUTTI
Radiology in Washington, DC
License number
DC 188072
Category
Radiology
Type
Surgery
License number
DC 188072
Category
Radiology
Type
Surgical Oncology
Address
Address
2
6900 Georgia Ave. NW, Washington, DC 20307
14013 Welland Ter, Gaithersburg, MD 20878
14013 Welland Ter, Gaithersburg, MD 20878
Phone
(202) 782-7341
(301) 217-0798
(301) 217-0798
Personal information
See more information about STEVEN KENNETH LIBUTTI at radaris.comName
Address
Phone
Rockville, MD
14013 Welland St, North Potomac, MD 20878
Professional information
Steven K Libutti, Bronx NY
Specialties:
Surgery, Surgical Oncology, Endocrinology, Diabetes & Metabolism, Medical Oncology
Work:
Montefiore Medical Center
3400 Bainbridge Ave, Bronx, NY 10467 MMC Medical Park at Eastchester
1575 Blondell Ave, Bronx, NY 10461 Montefiore Medical Center
600 E 233Rd St, Bronx, NY 10466 Montefiore Medical Center
1825 Eastchester Rd, Bronx, NY 10461 MMC ME Center For Cancer Care
1521 Jarret Pl, Bronx, NY 10461 Montefiore Medical Center
111 E 210Th St, Bronx, NY 10467 Walter Reed Army Medical Center
6900 Georgia Ave Nw, Washington, DC 20307 MMG Bronx East
2300 Westchester Ave, Bronx, NY 10462 MMG -Cross County
1010 Central Park Ave, Yonkers, NY 10704 Mmc Cham
3415 Bainbridge Ave, Bronx, NY 10467
3400 Bainbridge Ave, Bronx, NY 10467 MMC Medical Park at Eastchester
1575 Blondell Ave, Bronx, NY 10461 Montefiore Medical Center
600 E 233Rd St, Bronx, NY 10466 Montefiore Medical Center
1825 Eastchester Rd, Bronx, NY 10461 MMC ME Center For Cancer Care
1521 Jarret Pl, Bronx, NY 10461 Montefiore Medical Center
111 E 210Th St, Bronx, NY 10467 Walter Reed Army Medical Center
6900 Georgia Ave Nw, Washington, DC 20307 MMG Bronx East
2300 Westchester Ave, Bronx, NY 10462 MMG -Cross County
1010 Central Park Ave, Yonkers, NY 10704 Mmc Cham
3415 Bainbridge Ave, Bronx, NY 10467
Education:
Columbia University (1990), New York Presbyterian Hospital / Columbia (1995) *Surgery, National Cancer Institute (1996) *Surgical Oncology
Steven Kenneth Libutti, Bronx NY
Specialties:
Surgeon
Address:
111 E 210Th St, Bronx, NY 10467
Walter Reed Army Medical Ctr, Washington, DC 20307
Walter Reed Army Medical Ctr, Washington, DC 20307
Board certifications:
American Board of Surgery Certification in Surgery
Molecular-Based Method Of Cancer Diagnosis And Prognosis
US Patent:
2011031, Dec 29, 2011
Filed:
Feb 12, 2010
Appl. No.:
13/148851
Inventors:
Steven K. Libutti - North Potomac MD, US
Mei He - Rockville MD, US
Mei He - Rockville MD, US
Assignee:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND SERVICES - Bethesda MD
International Classification:
C40B 30/04, C40B 30/00, C12Q 1/68, C40B 40/04, C40B 40/10
US Classification:
506 9, 506 16, 506 18, 435 612, 506 7
Abstract:
A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. Thus, provided herein is a method of determining the prognosis of a subject with a tumor by detecting expression of five of more cancer survival factor-associated genes in a tumor sample and comparing expression of the five or more cancer survival factor-associated genes in the tumor sample to a control. In some examples, an increase in expression of ABCF1, CORO1C, DPP3, PREB, UBE3A, and PTDSS1 in a tumor sample compared to a control sample indicates poor prognosis. Also provided is a method of treating a patient diagnosed with cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed cancer survival factor-associated genes. Further provided are arrays including probes or antibodies specific for a plurality of cancer survival factor-associated genes or proteins.
Quantitative Assay Of The Angiogenic And Antiangiogenic Activity Of A Test Molecule
US Patent:
2005017, Aug 11, 2005
Filed:
Apr 9, 2003
Appl. No.:
10/510652
Inventors:
Steven Libutti - North Potomac MD, US
Mark Kayton - New York NY, US
Mark Kayton - New York NY, US
Assignee:
Government of the United States of America, repres by the Secretary, Dept. of Health and Human Serv. - Rockville MD
International Classification:
C12Q001/00
US Classification:
435004000
Abstract:
A method of measuring the angiogenic or antiangiogenic activity of a test molecule comprising (i) utilizing a modified CAM assay to assign an FVD value for a test region of interest and comparing this value to an FVD value for a control region of interest, or (ii) utilizing a modified CAM assay to determine the spectrophotometric absorbance value of a test region of interest and comparing this value to the spectrophotometric absorbance value of a control region of interest, wherein a lower value of the test region of interest as compared to the of the control region of interest is indicative of the test molecule being useful as an inhibitor of angiogenesis, and wherein a higher value of the test region of interest as compared to the value of the control region of interest is indicative of the test molecule being useful as a stimulator of angiogenesis.
Quantitative Assay Of The Angiogenic And Antiangiogenic Activity Of A Test Molecule
US Patent:
2005013, Jun 23, 2005
Filed:
Dec 16, 2004
Appl. No.:
11/014472
Inventors:
Steven Libutti - North Potomac MD, US
Mark Kayton - New York NY, US
Mark Kayton - New York NY, US
Assignee:
Government of the U.S.A.,represented by the Secretary, Department of Health & Human Services - Rockville MD
International Classification:
A61K049/00, G06F019/00, G01N033/48, G01N033/50, G06K009/00
US Classification:
424009200, 702019000, 382128000
Abstract:
A method of measuring the angiogenic or antiangiogenic activity of a test molecule comprising (i) utilizing a modified CAM assay to assign an FVD value for a test region of interest and comparing this value to an FVD value for a control region of interest, or (ii) utilizing a modified CAM assay to determine the spectrophotometric absorbance value of a test region of interest and comparing this value to the spectrophotometric absorbance value of a control region of interest, wherein a lower value of the test region of interest as compared to the of the control region of interest is indicative of the test molecule being useful as an inhibitor of angiogenesis, and wherein a higher value of the test region of interest as compared to the value of the control region of interest is indicative of the test molecule being useful as a stimulator of angiogenesis. Furthermore, such measurements of angiogenic or antiangiogenic activity may be monitored in an animal or patient afflicted with a disease.
Diagnostic Tool For Diagnosing Benign Versus Malignant Thyroid Lesions
US Patent:
7901881, Mar 8, 2011
Filed:
Apr 11, 2005
Appl. No.:
11/547995
Inventors:
Steven K. Libutti - North Potomac MD, US
Chiara Mazzanti - Pisa, IT
Martha Zeiger - Baltimore MD, US
Christopher Umbricht - Baltimore MD, US
Chiara Mazzanti - Pisa, IT
Martha Zeiger - Baltimore MD, US
Christopher Umbricht - Baltimore MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
The John Hopkins University - Baltimore MD
The John Hopkins University - Baltimore MD
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435 6, 435 71
Abstract:
The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer.
Filip1L Compositions And Methods For Treating Cancer
US Patent:
2014003, Feb 6, 2014
Filed:
Jul 26, 2013
Appl. No.:
13/952192
Inventors:
Steven K. Libutti - North Potomac MD, US
Mijung Kwon - Frederick MD, US
Anita Tandle - Towson MD, US
Mijung Kwon - Frederick MD, US
Anita Tandle - Towson MD, US
Assignee:
The United States of America, as Represented by the Secretary, Department of Health & Human Servic - Bethesda MD
International Classification:
C07K 14/47
US Classification:
514 44 R, 536 235, 4353201, 435325, 435366, 435348, 435419, 43525411, 4352542
Abstract:
A purified DOC1 polypeptide comprising a fragment of SEQ ID NO: 1 is provided, wherein the DOC1 polypeptide is not the full-length DOC1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting angiogenesis. A method of inhibiting tumor growth in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting tumor growth.
Filipil Compositions And Methods For Treating Cancer
US Patent:
8501912, Aug 6, 2013
Filed:
Dec 8, 2008
Appl. No.:
12/745279
Inventors:
Steven K. Libutti - North Potomac MD, US
Anita Tandle - Towson MD, US
Anita Tandle - Towson MD, US
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC
International Classification:
A61K 38/00, A61P 35/00, C07K 14/00
US Classification:
530350, 4241851, 514 133, 514 192, 530300
Abstract:
A purified DOC1 polypeptide comprising a fragment of SEQ ID NO: 1 is provided, wherein the DOC1 polypeptide is not the full-length DOC1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting angiogenesis. A method of inhibiting tumor growth in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting tumor growth.
Method For Diagnosing The Stage Of A Thyroid Tumor
US Patent:
2011017, Jul 21, 2011
Filed:
Feb 10, 2011
Appl. No.:
13/024845
Inventors:
Steven K. Libutti - North Potomac MD, US
Chiara Mazzanti - Pisa, IT
Martha Zeiger - Baltimore MD, US
Christopher Umbricht - Baltimore MD, US
Chiara Mazzanti - Pisa, IT
Martha Zeiger - Baltimore MD, US
Christopher Umbricht - Baltimore MD, US
International Classification:
C40B 30/06, C12Q 1/68
US Classification:
506 10, 435 614, 435 611
Abstract:
The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer.